Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment
US9375488B2 · kind B2 · utility
1Cited by
11References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 11, 2014 |
| Grant date | Jun 28, 2016 |
| Priority date | — |
| Expiry date | Dec 11, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.